Brief: Acurx Announces New Data From Phase 2A Clinical Trial Of C. Difficile Treatment
08/11/2021 13:27
Nov 8 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES NEW MICROBIOME DATA FROM ITS PHASE 2A
CLINICAL
TRIAL OF IBEZAPOLSTAT FOR CDI AT THE 9TH INTERNATIONAL C. DIFF.
CONFERENCE
* ACURX PHARMACEUTICALS INC - RESULTS SUPPORT EXPECTATION
THAT
MICROBIOME EFFECTS MAY BE PREDICTIVE OF BENEFICIAL OUTCOMES, LOW
RATES OF RECURRENCE
* ACURX PHARMACEUTICALS INC - PHASE 2B TRIAL COMPARING
IBEZAPOLSTAT TO VANCOMYCIN IN CDI PATIENTS TO BEGIN THIS MONTH
Source text for Eikon: ID:nPn3wqm8Xa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln